callahamirykaan1884.blogspot.com
Sauter joined Avigen in Novembedr 1999as controller. Previously he workede with the capital markets trading businessesd for and earned his CPAwith . At Avigeb he has been responsible forthe company's reporting to the Securitiex and Exchange Commission and Sarbanes-Oxley compliance. In April 2005, Avigejn (NASDAQ: AVGN) announced that it was exitin g the gene therapy business that it had workede on for 13 years and would insteae focus on developing therapies forneurologicalo diseases. Avigen sold its gene therapy businese last monthto (NASDAQ: GENZ) of Cambridge, for $12 million plus milestone paymenta and royalties on any products developede from the deal.
Paulson, who has been with Avige for more thannine years, said in a statementy that his experience at Avigen has been and that he has been pleased to have been part of the transition over the past year. He said he plans to use his experiences tohelp "grow and other emerging companies.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment